CLEVELAND, Ohio — University Hospitals is participating in a trial evaluating antibodies created in a lab as a possible treatment for early-stage COVID-19.
UH is one of 25 sites taking part in ACTIV-2, a program that includes both Phase 2 and Phase 3 randomized and blinded trials of a variety of substances compared to placebo, the hospital system said in a statement Thursday.
The study’s goal is to find a treatment that keeps COVID-19 patients out of the hospital, UH said.
The ACTIV-2 program is evaluating an experimental monoclonal antibody treatment known as LY-CoV555, developed by Eli Lilly and Company, UH said. Monoclonal antibodies are antibodies produced in a lab. The antibodies in the ACTIV-2 trial attack the coronavirus and prevent it from getting into cells, UH said. LY-CoV555 is administered as an infusion — a continuous slow introduction of a solution — into a vein in the arm.
ACTIV-2 is part of the National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership program to speed development of the most promising treatments and vaccines. ACTIV-2 is supported by Operation Warp Speed, the federal government’s effort to speed up the development of COVID-19 vaccines and medicines.
The UH treatment trial will enroll people who tested positive for COVID-19 within seven days, felt symptoms within 10 days of enrolling in the study, and are not hospitalized, UH said.
Experimental coronavirus vaccines: When they will roll out, side effects and what it all means for you
UH wants half of its study participants to be at high risk for severe COVID-19, including being 55 or older, and having chronic lung, kidney, or liver disease; obesity; hypertension; cardiovascular disease; diabetes; or moderate to severe asthma.
The study will take place at UH in collaboration with Case Western Reserve University School of Medicine.
Dr. Jeffrey Jacobson, attending physician in the Division of Infectious Diseases and HIV Medicine at UH, and professor of medicine at CWRU School of Medicine, is principal investigator. Dr. Leila Hojat, attending physician in the division of Infectious Diseases and HIV Medicine at UH Cleveland Medical Center, and assistant professor of medicine at CWRU School of Medicine, is co-investigator.
UH is also participating in trials for proposed COVID-19 vaccines from AstraZeneca and Pfizer.
For information about enrolling in the trial at University Hospitals, call 1-833-78-TRIAL, email [email protected], or click here.
©2020 The Plain Dealer, Cleveland
Visit The Plain Dealer, Cleveland at www.cleveland.com
Distributed by Tribune Content Agency, LLC.